In Phase I of the NHLBI trial of Thrombolysis in Myocardial Infarction (TIMI), 290 patients admitted within 7 hr after onset of acute infarction were randomly assigned to intravenous treatment with either streptokinase (SK) or recombinant tissue-type plasminogen activator (rt-PA). Left ventricular function was measured from contrast ventriculograms in 145 patients with both pretreatment and predischarge studies analyzable. Regional wall motion in the infarct site was measured by the centerline method and expressed in units of standard deviations (SDs) from the mean motion in 52 normal subjects. Patients treated with rt-PA (n = 77) achieved a significantly higher reperfusion rate after 90 min of treatment. Perfusion of the infarct-related artery improved from visual grade 0 or 1 (total occlusion or penetration without perfusion) to grade 2 or 3 (partial or full reperfusion) in 62% receiving rt-PA vs 31% receiving SK (n = 68) (p < .001). However, the ejection fraction did not change significantly from before treatment to before discharge in either treatment group (+0.7 6.7% vs + 1.0 8.3%, respectively). A small but significant increase in regional wall motion was observed in each of the two groups (+0.4 0.8 vs +0.3 0.8 SD/chord, respectively; each p < .001 compared with baseline). This was countered by declines in the hyperkinesis of the noninfarct region (-0.3 + 1.0 SD/chord [p = .01] compared with baseline and -0.2 1.0 SD/chord [p = .23], respectively).
tional class. These studies have used diverse protocols, and in many protocols treatment was begun quite late after the onset of the clinical event; in others the dosage of the thrombolytic agent was relatively low. Pooling of the data available in 1983 for streptokinase, the most widely studied drug, suggested a favorable influence on outcome in acute myocardial infarction, which has recently been confirmed. 2 To evaluate further the potential benefit of thrombolytic therapy, the National Heart, Lung, and Blood Institute is sponsoring the Thrombolysis in Myocardial Infarction (TIMI) trial, which began in 1983. The trial is being conducted in two phases: Phase I compared the efficacy of intravenous tissue-type plasminogen activator (t-PA) and intravenous streptokinase in achieving reperfusion; Phase II, currently in progress, is studying the effects of coronary angioplasty in addition to thrombolytic therapy on mortality, cardiovascular events, and left ventricular function.
Phase I began on August 15, 1984 , and was stopped on February 5, 1985 , because the reperfusion rate was significantly greater after treatment with t-PA than with streptokinase.' The reperfusion results are the subject of a separate report. We report here findings on the effect of thrombolytic therapy on left ventricular function assessed from pretreatment and predischarge contrast ventriculograms.
Methods
Thrombolytic therapy. Patients were enrolled and treated at 13 clinical sites. In addition there is a drug distribution center; blood coagulation, electrocardiographic, pathologic, radiographic, and radionuclide core laboratories; and a data coordinating center (Appendix).
Patients were eligible if they had experienced at least 30 min of ischemic chest pain and ST segment elevation of 0.1 mV or more in at least two electrocardiographic leads reflecting one zone of infarction. Exclusion criteria were duration of chest pain over 7 hr; age over 75 years; uncontrolled hypertension; cerebrovascular events, severe streptococcal infection, previous streptokinase infusion, or severe trauma within the last 6 months; current oral anticoagulant therapy; past or present bleeding disorder or significant gastrointestinal bleeding; surgery or cardiopulmonary resuscitation within the last 2 weeks; prior coronary artery bypass graft surgery; presence of left bundle branch block, prosthetic heart valve, or dilated cardiomyopathy; shock unresponsive to volume expansion and vasopressor therapy; or other advanced illness.
After providing informed consent, eligible patients had immediate cardiac catheterization. A 5000 U intravenous bolus of heparin was given. Left ventriculography was performed with a power injection of not less than 35 ml of contrast medium and images were recorded on cine film in the 30 degree right anterior oblique projection. Angiograms of the noninfarct and infarctrelated coronary arteries (as judged from the electrocardiogram and ventriculogram) were then obtained. Patients with less than 50% diameter reduction in the infarct-related artery at baseline or after intracoronary administration of 200 ,ug of nitroglycerin were not given thrombolytic agents. The remaining patients were randomly assigned to one of two thrombolytic regimens. Patients assigned to streptokinase (SK) (supplied by Hoechst-Roussel Pharmaceuticals or Kabi Vitrum) received 1.5 million U intravenously over 1 hr. Patients assigned to recombinant t-PA (rt-PA) (Genentech, Inc., preparation No. G1 1021) received 80mg intravenously over 3 hr (40 mg, 20 mg, and 20 mg in the first, second, and third hours, respectively). This form of rt-PA is principally the double-chain variety. To maintain blinding, each patient received both an active agent and a placebo in concomitant 1 hr and 3 hr infusions through separate intravenous lines. Angiograms of the infarct-related artery were obtained 10, 20, 30, 45, 60, 75 , and 90 min after initiating thrombolytic therapy. At the conclusion of the angiographic study, a grid of known dimension was filmed at the patient's midchest level with the imaging equipment in the same position as during ventriculography.
Patients then received routine coronary care plus intravenous heparin at 1000 U/hr beginning 3 hr after the initial bolus, adjusted as needed to maintain the partial thromboplastin time at 1.5 to 2 times normal. The protocol called for repeat cardiac catheterization with ventriculography and coronary angiography 8 to 10 days later, i.e., before hospital discharge. Data analysis. The perfusion status of the infarct-related artery in the pretreatment and predischarge studies was assessed from the coronary arteriogram by the radiographic core laboratory using TIMI criteria (table 1) . For the analyses in the present report, the assessments of the core laboratory were used. Collaterals to the infarct artery were evaluated from the pretreatment angiogram and graded on a three-point scale as absent, minimal, or well-developed. Left ventricular ejection fraction and wall motion were measured at the radiographic core laboratory without knowledge of the coronary anatomy or results of thrombolytic therapy. The cine films were projected and the end-diastolic and end-systolic endocardial contours were traced from the frames with maximum and minimum volume, respectively, from a normal, non-postpremature sinus beat. No attempt was made to correct for the translational motion of the heart within the chest because (1) the methods described thus far for such correction are arbitrary and empirical4 and (2) the apex is an unreliable landmark for realigning the end-diastolic and endsystolic contours.5' 6 Left ventricular volume was calculated by the area-length method.7 A correction factor for magnification and distortion was derived from measurement of the filmed grid. Wall motion was measured by the centerline method along 100 chords constructed perpendicularly to a centerline drawn midway between the end-diastolic and end-systolic contours (figure 1), corrected for heart size, and expressed in units of standard deviations (SDs) from the mean motion in 52 normal subjects. These subjects were patients suspected of having heart disease who underwent diagnostic cardiac catheterization but who were found to have normal cardiac anatomy, normal coronary arteries, and normal ventricular function.
Abnormality in wall motion was calculated by two approaches. First, the severity of hypokinesis in the infarct site was calculated as the mean motion of chords lying in the most hypokinetic 50% of the infarct artery territory, and expressed in SD/chord. Hyperkinesis was similarly calculated in the most hyperkinetic 50% of the artery territory opposite the infarct site.
The derivation ofthis method has been described previously.`'0 Second, the circumferential extent of hypokinesis was also calculated as the set of contiguous chords having motion more However, the rate of entry of contrast material into the vessel distal to the obstruction or its rate of clearance from the distal bed (or both) are perceptibly slower than its entry into or clearance from comparable areas not perfused by the previously occluded vessel, e.g., the opposite coronary artery or the coronary bed proximal to the obstruction. Grade 3 (complete perfusion): Antegrade flow into the bed distal to the obstruction occurs as promptly as antegrade flow into the bed proximal to the obstruction, and clearance of contrast material from the involved bed is as rapid as clearance from an uninvolved bed in the same vessel or the opposite artery. depressed than 1 or 2 SD below the normal mean and expressed as a percentage of the endocardial contour length. Nearby hypokinetic chords were included in the hypokinetic segment if the discontinuity separating them appeared to be caused by noise in the tracing and was five chords or less wide.
To measure the severity of stenosis in the infarct-related artery, the coronary cineangiogram at the conclusion of thrombolytic therapy was projected and the contours of the infarct artery lumen at the thrombosis site were traced two or three times by each of two observers and digitized. The diameter of the lumen was measured along chords constructed perpendicularly to a centerline drawn in midlumen and corrected for image magnification and pincushion distortion as described previous- CHORD NUMBER FIGURE 1. Centerline method of regional wall motion analysis. A, End-diastolic and end-systolic left ventricular endocardial contours and centerline constructed by the computer midway between the two contours. B, Motion is measured along 100 chords constructed perpendicular to the centerline. C, Motion at each chord is normalized by the enddiastolic perimeter to yield a shortening fraction. Motion along each chord is plotted for the patient (solid line). The mean motion in the normal ventriculogram group (dashed line) and 1 SD standard deviation above and below the mean (dotted lines) are shown for comparison. D, Standardized motion. The wall motion of the patient is now plotted in units of SDs from the normal mean (dotted line). The ly.1`The minimum diameter and percent diameter reduction were calculated.
Statistical methods. Means and standard deviations were computed for continuous variables and differences in means between the two treatment groups were assessed statistically by means of a t statistic. 12 Evaluations of changes over time were made with a matched-pairs t test. 12 The Wilcoxon test'3 was used to compare the treatment groups with respect to ranks of a continuous variable. Binary variables were compared between the treatment groups with a Z test of two proportions.14 Treatment differences in proportions were compared among two or more subgroups defined by baseline characteristics with a log odds ratio procedure.14
Results
Patients. In Phase I of TIMI, 290 patients were assigned to receive rt-PA (n = 143) or SK (n = 147). Examination of baseline characteristics reveals that the two treatment groups were similar in all clinical and angiographic variables tested.3* Predischarge cardiac catheterization was not performed in 78 patients (27% of 290) because of patient or physician refusal (34, 12%), death (11, 4%), coronary artery bypass graft surgery or angioplasty during the hospitalization (19, 7%), medical contraindications to angiography (12, 4%) or other reasons (2, 1%). Of the 212 patients with predischarge studies, 67 had ventriculograms that could not be analyzed for technical reasons. Paired ventriculographic data are therefore available in 145 patients (50% of the 290). These data constitute the subject of the present report.
The characteristics of patients with paired ventriculographic data (n = 145) were compared with those without such data (table 2) (n = 145). The latter were significantly older and had a higher proportion of circumflex and a lower proportion of right coronary artery thrombosis. The reperfusion rate was identical (46%) in the two groups; however, the 145 patients without paired data comprised a group of 78 with no predischarge catheterization whose reperfusion rate was 26% plus a group of 67 lacking paired left ventricular function data due to technical problems whose reperfusion rate was 68%. The patients without paired angiographic data had a significantly higher incidence of in-hospital complications and of course included those who died (table 2) .
Results of thrombolytic therapy. There were no significant differences in baseline clinical or angiographic variables between the 68 SK-and 77 rt-PA-treated patients in whom this study was carried out (table 3) .
In patients receiving rt-PA who had grade 0 perfu-*For three of 39 baseline characteristics tested, the p value for differences between the two treatment groups was less than .05, the smallest being .014; this finding is not inconsistent with random assignment of .03
Mitral regurgitation (%) ANumber of vessels with stenosis .70%.
BPerfusion status based on core laboratory visual assessment of perfusion in the infarct-related artery at baseline and 90 min after initiation of thrombolytic therapy (see table 1 ). sion at baseline (n = 47) , reperfusion to grade 2 or 3 at 90 min was achieved in 53%. This was more frequent than in patients receiving SK (26% of 51; p < .005). When patients with either grade 0 or grade 1 at baseline were combined, reperfusion to grade 2 or 3 at 90 min was achieved in 62% of 58 patients treated with rt-PA but in only 31% of 59 patients treated with SK (p < .0006). These reperfusion rates are similar to the rates observed in the entire study population of 290 patients. For patients with a subtotal occlusion (grade 2 or 3) at baseline, treatment with rt-PA increased the proportion of patients having grade 3 perfusion from 26% at baseline to 74% at 90 min (p < .008, n = 19), whereas SK did not cause a significant increase in perfusion status (44% had grade 3 perfusion at baseline, 56% grade 3 at 90 minm n = 9). 820 The reocclusion rate at the predischarge cardiac catheterization was similar in the two treatment groups, resulting in a higher rate of sustained reperfusion (grades 2 and 3) with rt-PA (29 [50%] of 58 patients with grade 0 or 1 perfusion at baseline) than with SK (16 [27%] of 59; p < .01).
Effect of thrombolytic therapy on left ventricular function (table 4). Despite the difference in reperfusion rate noted in vessels treated with SK or rt-PA, there was no difference between the two treatment groups in either the magnitude of improvement in ventricular function or the level of function measured before discharge. The ejection fraction did not change significantly in either treatment group, and wall motion in the infarct site improved significantly in both groups. Hyperkinesis in the noninfarct site decreased in both groups, but CIRCULATION AThese measures are indexed to body surface area.59
BDifferent group sizes are specified in parentheses.
this decrease was significant only in the rt-PA group. The end-diastolic, end-systolic, and stroke volume indexes and cardiac index were similar for the two thrombolytic agents at the early and predischarge studies. Subdivision by infarct location (anterior, inferior) and examination of only those patients with initially depressed function (ejection fraction < 35%) also failed to demonstrate any differences between rt-PAand SK-treated groups in regard to recovery of ventricular function. The analyses in table 4 were based on the 145 patients with paired (baseline and predischarge) ventriculogram readings, or 50% of the total study group. Ventriculogram readings were missing either at baseline or predischarge in 46.2% (66/143) of the patients treated with rt-PA and in 53.7% (79/147) of the patients treated with SK. Two methods of imputing missing predischarge minus baseline changes in ejection fraction and hypokinesis were tried to assess the impact of the missing data. The first method used regression models based on the 145 patients with paired Vol. 75, No. 4, April 1987 readings to impute ventricular function changes for the 145 patients with missing readings. Regression equations were obtained for three groups of patients: (1) those having both baseline and predischarge ventriculograms but one or both not read for technical reasons, (2) those missing the predischarge ventriculogram because of intervening death or other serious medical complications, and (3) those missing the predischarge ventriculogram for other reasons. In each regression analysis, coronary artery perfusion grades at baseline, 90 min after initiation of treatment, and before discharge (when available) were used as regressor variables. The findings of this method of imputation did not differ substantially from those presented in table 4.
A second method of imputation involved assigning "worst possible" ejection fraction and hypokinesis values for those patients with missing ventriculogram readings and doing Wilcoxon rank analyses of the data for differences between the treatment groups. Because there was a larger percentage of missing readings in the SK group, this method of imputation tended to push the treatment differences with respect to ejection frac-To investigate the reason why the change in ventriction and hypokinesis toward a benefit with rt-PA. ular function did not differ between treatment groups However, even with this extreme approach to imputa-despite the higher reperfusion rate achieved with rttion, there were no statistically significant treatment PA, factors that may influence reperfusion or recovery differences.
of function were examined. None of the baseline char- acteristics tested (location of infarct-related artery, number of vessels with > 70% diameter stenosis, history of prior infarct) had a significant influence. Also, the time to reperfusion did not differ significantly between SKand nt-PA-treated patients who had grade 0 or 1 perfusion before treatment and grade 2 or 3 perfusion by 90 min (5.3 + 1.8 [n = 18] vs 5.8 + 1.8 hr [n = 36], respectively). Actually reperfusion occurred earlier after administration of rt-PA than after SK (0. 8 ± 0.4 vs 1.0 ± 0.3 hr; p = NS) but rt-PA was substantially'5 more successful than SK in achieving reperfusion in patients treated later than 4 hr after symptom onset, which made the mean time to treatment appear longer in the rt-PA group who had reperfusion (5.0 ± 1.6 vs 4.3 ± 1.8 hr for SK; p = NS). Subgroup analysis. To evaluate the effect of perfu- sion status on ventricular function, the patients in the two treatment groups were combined. As noted in table 5, the subgroups defined by reperfusion status were comparable in level of regional and global ventricular dysfunction before treatment. There was a small but significant increase in ejection fraction and in regional wall motion in the infarct site in patients who achieved sustained reperfusion (reperfusion by the 90 min angiogram without reocclusion in the predischarge arteriogram) or who had subtotal occlusion in both studies. The circumferential extent of hypokinesis more severe than 1 SD below normal did not decrease significantly in any subgroup, and the extent of hypokinesis more than 2 SD below normal decreased significantly only in patients with subtotal occlusion initially. min angiogram), with no reperfusion, or who experienced reocclusion between the baseline and predischarge arteriogram had no significant change in either regional or global function. The SK reperfusion rate tended to be higher in patients treated less than 4 hr after symptom onset than later (45.5% [n = 22] vs 21.6% [n = 371, respectively, p = .054). Therefore, subgroup analysis was also performed in patients divided by time to reperfusion (< 4 hr vs 4 hr). This showed a trend toward greater improvement in ejection fraction in patients with sustained reperfusion of a totally occluded artery if they were reperfused earlier than 4 hr after symptom onset (3.3 5.2%, n = 10) rather than later (1.7 + 6.9%, n = 35; p = NS). The time-dependency of the improvement in global function reflected the significantly greater improvement in regional wall motion in the infarct site in early-reperfused patients (0.7 + 0.6 vs 0.2 0.4 SD/chord; p = .04) (figure 2). When time to treatment (< 4 hr vs 4 hr) was analyzed rather than time to reperfusion, similar trends were seen but without significance.
Comparison of patients with vs without collaterals to the territory supplied by the infarct-related artery showed.highly significant differences (table 6 ). In the group as a whole, the ejection fraction increased (+2.3 + 7.5; p = .06) in the patients with either 824 minimal or well-developed collaterals but not in patients with no collaterals (+0.3 7.4%; p = NS). This was not because of a difference in the degree of recovery in wall motion in the infarct site, which was similar in the patients with vs without collaterals. Instead, the change in ejection fraction reflected the influence of motion of the noninfarct region, which decreased significantly in the patients without collaterals but did not change in those with collaterals. Since collateral development and flow require adequate perfusion pressure from the supplying artery,'6 patients with collaterals to the infarct-related artery probably did not have severe stenosis of the noninfarct arteries. Therefore the observation that hyperkinesis persisted in patients with collaterals but subsided in patients without collaterals may be due to the availability of adequate perfusion in the noninfarct region in those with collaterals to support hyperkinesis.'7 Although the presence of single-vessel disease and normal perfusion of the noninfarct region has been associated with increased incidence of compensatory hyperkinesis during acute infarction,'8 having collaterals to the infarctrelated artery did not correlate with increased hyperkinesis in our study, perhaps because the necessary flow was diverted to supply the infarct-related artery. The difference in functional recovery between patients with vs without collaterals was most marked in the subgroup who had late reperfusion. Patients without reperfusion did not improve regardless of collateral status. Improvement in left ventricular function after reperfusion tended to be greater in patients with severely depressed function early. In five of 45 patients with sustained reperfusion, the pretreatment ejection fraction was under 35% and improved by 6 ± 4% (p < .05 vs pretreatment value). In comparison, patients with a pretreatment ejection fraction of at least 35% had an increase of only 2 + 7% (p = NS). Similar trends were seen among patients with late reperfusion or subtotal occlusion. The severity of residual stenosis at 90 min did not exert a significant influence on subsequent recovery of ventricular function. Fifteen percent of 75 patients with a minimum stenosis diameter of 0.3 mm or less had greater than 1 SD improvement in wall motion, and 21% of 70 patients with more patent arteries improved their wall motion by this amount (p = .29). In the subgroup with sustained reperfusion from baseline grade 0 or 1, a greater than 1 SD improvement in wall motion was seen in only five (13%) of 38 patients with a relatively patent artery and in none of seven patients with a severe residual stenosis (p = .41).
Discussion
The purpose of the Phase I TIMI trial was to compare the efficacy of intravenous SK and rt-PA in achieving reperfusion of occluded coronary arteries in patients with acute myocardial infarction. The results have shown that rt-PA produces a significantly higher reperfusion rate than does SK.3 A secondary end point of this trial was comparison of the effects of the two thrombolytic agents on left ventricular function. Accordingly, we tested the hypothesis that reperfusion of the infarct-related artery by thrombolytic therapy salvages myocardial function, presumably by reducing infarct size, and may thereby enhance survival after infarction.
Both global and regional left ventricular function were assessed in this study. The left ventricular ejection fraction correlates only roughly with infarct size"92' but has consistently proven to be a powerful predictor of survival after myocardial infarction. [22] [23] [24] [25] [26] [27] However, in studies of ventricular function during the early hours of acute infarction, the ejection fraction appears to be a relatively insensitive measure of the severity of hypokinesis in the infarct region because of the influence of compensatory hyperkinesis or other wall motion abnormalities in the noninfarct region.9 ' 28 Also, the subsequent decrease in hyperkinesis after infarction tends to negate the effect of recovery in hypokinesis on the global ejection fraction. This influence of the noninfarct region's motion on the ejection fraction can be seen in our analysis of the effect of collaterals. Several studies suggest that assessment of regional function may be a better predictor of survival than the ejection fraction,2`32 although not all agree. 33 This analysis showed that patients with sustained reperfusion after receiving either rt-PA or SK demonstrated significant improvement in regional ventricular function at the infarct site and in the global ejection fraction. Since no control group was used, we do not know whether this improvement might have occurred in the absence of thrombolytic therapy. However, patients who failed to achieve reperfusion or who experienced reocclusion of the infarct-related artery exhibited no improvement in regional or global ventricular function.
These results lie in the middle range of published reports concerning the effect of thrombolytic therapy on left ventricular function. Of five randomized controlled trials of intracoronary SK, one demonstrated improved global function in the treated group,34 whereas the others did not. 35 38 Of the uncontrolled trials of intracoronary or intravenous therapy with angiographic documentation of reperfusion, some found improved global function in reperfused patients,3942 some found improved regional but not global function,28 43A45 and some found improved regional function only in a selected subset of patients who achieved reperfusion.6 '47 There are several possible reasons for these variable results. First, and perhaps most importantly, the time delay from onset of symptoms to initiation of thrombolytic therapy has been most consistently identified as a significant factor influencing recovery of ventricular function.39 "47-1 In agreement with these studies and with the results of experimental studies,52'53 the present data also show enhanced myocardial salvage with earlier reperfusion. It should be noted that patients experiencing reperfusion by rt-PA achieved opening slightly earlier after onset of therapy than did the SK-treated patients.
Another important reason for the variable results of previous studies is patient selection. For example, patients with subtotal occlusion were randomized in the study by Anderson et al. 34 but treated as a separate group in that by Leiboff et al. 35 Administration of thrombolytic therapy under angiographic observation leads to selection of patients well enough to tolerate early cardiac catheterization. As a result, the potential benefit of thrombolytic therapy may be underestimated since (1) left ventricular function improves more after reperfusion in patients with severely depressed function early, as seen in previous reports38 50, 54 and in the present study, and (2) reperfusion reduces mortality most significantly in those with the most impaired hemodynamic state.55 Patient selection also occurs through refusal to undergo follow-up testing. Comparability of patients with and without follow-up tests of ventricular function has rarely been analyzed in previous reports, making it impossible to determine whether this can explain the differences in results. In the present analysis, the study group had fewer inhospital complications than the patients without paired ventriculographic data, but the reperfusion rate was the same and imputation of missing data did not alter the results.
A third factor that may explain the different results of the various trials of thrombolytic therapy is the unknown adequacy of reperfusion. Although it has long been known that reperfusion with thrombolytic therapy usually leaves a severe residual stenosis in the infarct-related artery,56 it is only recently that quantitative analysis of the stenosis severity has demonstrated a significant correlation between the severity of the residual stenosis and the risk of reocclusion.57 58 Even without reocclusion, the presence of a severe residual stenosis precludes recovery of ventricular function in patients who achieve reperfusion.0 In this study, the functional recovery rate was not significantly related to the stenosis diameter at 90 min. However, so few of the patients with sustained reperfusion from grade 0 or 1 to grade 2 or 3 had greater than 1 SD improvement in wall motion (only 1 1% [5 of 45] in the present study vs 41% [12 of 29] in the previous report') that it would be difficult to demonstrate a relationship. The limited recovery that occurred even in patients who achieved sustained reperfusion indicates that other factors, such as the prolonged time to reperfusion, may have been dominant. In contrast, the reocclusion rate was related significantly to the residual stenosis at 90 min, which averaged 0.3 ± 0.2 mm in minimum diameter in arteries that reoccluded vs 0.6 ± 0.3 mm in persistently patent arteries (p = .036). Since no functional recovery was seen in patients suffering reocclusion, it will be important to determine from Phase II of TIMI whether dilatation to reduce a residual stenosis benefits the patient by enhancing functional recovery or by preventing reocclusion.
In summary, our results indicate that in the group as a whole, intravenous thrombolytic therapy by SK or rt-PA results in a small but significant improvement in regional wall motion in the infarct site. The magnitude of the improvement is inadequate to effect a change in global function unless sustained reperfusion is achieved or unless the occlusion is initially subtotal. Significantly greater functional recovery was seen in patients who had reperfusion earlier than 4 hr after symptom onset. Patients who achieved reperfusion late, after the 90 min angiogram, exhibited functional recovery only if they had collaterals to the infarct region.
Phase I of the TIMI trial has demonstrated a reperfusion rate with intravenous rt-PA comparable to that of intracoronary therapy. In view of the time dependence of functional recovery, it is hoped that earlier treatment of patients enrolled in Phase II will result in a greater improvement in function than was noted in the present study and that the level of functional improvement will be adequate to reduce mortality after infarction.
